Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer
NCT07752550Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University
- Start
- Jul 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
A Phase 2 trial of retlirafusp alfa in triple-negative breast cancer (TNBC), sponsored by Harbin Medical University. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
retlirafusp alfa
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07752550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07752550.